ATE415472T1 - Humanantikörper gegen blutgerinnungsfaktor viii - Google Patents

Humanantikörper gegen blutgerinnungsfaktor viii

Info

Publication number
ATE415472T1
ATE415472T1 AT02738656T AT02738656T ATE415472T1 AT E415472 T1 ATE415472 T1 AT E415472T1 AT 02738656 T AT02738656 T AT 02738656T AT 02738656 T AT02738656 T AT 02738656T AT E415472 T1 ATE415472 T1 AT E415472T1
Authority
AT
Austria
Prior art keywords
fviii
factor viii
human
against blood
scfv
Prior art date
Application number
AT02738656T
Other languages
English (en)
Inventor
Toshihiro Nakashima
Masato Yuguchi
Original Assignee
Chemo Sero Therapeut Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeut Res Inst filed Critical Chemo Sero Therapeut Res Inst
Application granted granted Critical
Publication of ATE415472T1 publication Critical patent/ATE415472T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
AT02738656T 2001-06-12 2002-06-11 Humanantikörper gegen blutgerinnungsfaktor viii ATE415472T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001177640 2001-06-12

Publications (1)

Publication Number Publication Date
ATE415472T1 true ATE415472T1 (de) 2008-12-15

Family

ID=19018448

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02738656T ATE415472T1 (de) 2001-06-12 2002-06-11 Humanantikörper gegen blutgerinnungsfaktor viii

Country Status (12)

Country Link
US (1) US7214785B2 (de)
EP (1) EP1396539B1 (de)
JP (1) JP4205576B2 (de)
KR (1) KR100925348B1 (de)
AT (1) ATE415472T1 (de)
AU (1) AU2002313194B9 (de)
CA (1) CA2418808A1 (de)
DE (1) DE60230037D1 (de)
DK (1) DK1396539T3 (de)
ES (1) ES2316574T3 (de)
PT (1) PT1396539E (de)
WO (1) WO2002101040A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
JP4934796B2 (ja) 2003-08-14 2012-05-16 トロンボジェニクス・ナムローゼ・フエンノートシャップ 可変抗体
CA2616902A1 (en) 2005-07-29 2007-02-15 Life Sciences Research Partners Vzw Human inhibitory anti-factor viii antibodies binding to the a2 domain
EP2333555A1 (de) * 2009-12-09 2011-06-15 Siemens Healthcare Diagnostics Products GmbH Heterogener Gerinnungstest
WO2014075205A1 (zh) * 2012-11-15 2014-05-22 Cai Shenghe 一种凝血八因子及其变异体纯化方法
US11090373B2 (en) * 2015-12-04 2021-08-17 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Antigen-specific T cells for inducing immune tolerance
WO2018111010A1 (ko) * 2016-12-14 2018-06-21 (주) 팬젠 항-혈액응고 제viii인자 항체 및 그 용도
US11155635B2 (en) 2016-12-14 2021-10-26 Pangen Biotech Inc. Anti-coagulation factor VIII antibody and use thereof
CN108409863B (zh) * 2017-02-10 2023-09-26 上海仁会生物制药股份有限公司 抗凝血因子xi抗体
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2838166B2 (ja) 1989-11-10 1998-12-16 バクスター、インターナショナル、インコーポレイテッド 第▲ｖｉｉｉ▼因子阻害剤産生の抑制のための医薬組成物および方法
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
ES2283308T3 (es) * 1999-07-14 2007-11-01 D. Collen Research Foundation Vzw Anticuerpo monoclonal para el factor viii, que incluso cuando esta presente en exceso molar inactiva el factor viii solo en parte y metodo para producir dicho anticuerpo.
AU2001234125A1 (en) * 2000-02-22 2001-09-03 Medical And Biological Laboratories Co., Ltd. Antibody library

Also Published As

Publication number Publication date
AU2002313194B2 (en) 2007-12-13
WO2002101040A1 (en) 2002-12-19
AU2002313194B9 (en) 2008-06-05
EP1396539B1 (de) 2008-11-26
PT1396539E (pt) 2009-02-06
KR20030029128A (ko) 2003-04-11
AU2002313194B8 (en) 2002-12-23
US20040120951A1 (en) 2004-06-24
US7214785B2 (en) 2007-05-08
ES2316574T3 (es) 2009-04-16
DE60230037D1 (de) 2009-01-08
CA2418808A1 (en) 2002-12-19
EP1396539A4 (de) 2004-07-28
DK1396539T3 (da) 2009-02-09
JPWO2002101040A1 (ja) 2004-09-24
KR100925348B1 (ko) 2009-11-09
EP1396539A1 (de) 2004-03-10
JP4205576B2 (ja) 2009-01-07

Similar Documents

Publication Publication Date Title
ATE389721T1 (de) Agonistische antikörper gegen den thrombopoietinrezeptor und deren therapeutische verwendungen
SI1624891T2 (sl) Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije
ATE548386T1 (de) Synthetische immunglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
CY1116167T1 (el) Φαρμακευτικeς συνθεσεις κατευθυνομενες σε υποδοχεις erb-b1
ATE531812T1 (de) Humanisierung von nager-antikörpern
ATE476994T1 (de) Antikörper gegen gpnmb und ihre verwendungen
CY1108545T1 (el) Πρωτεϊνες υπομοναδας υποδοχεα κυτοκινης θηλαστικου, σχετικα αντιδραστηρια και μεθοδοι
CY1107708T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα για υποδοχεα παραγοντα επιδερμικης αναπτυξης
EP1575484A4 (de) Humanisierte immunomodulatorische monoklonale antikörper zur behandlung von neoplastischen erkrankungen oder immunschwäche
CA2469833A1 (en) Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them
DE69737683D1 (de) Antikörper gegen die ed-b domäne von fibronektin, ihre herstellung und verwendungen
JP2004527212A5 (de)
JP2002531090A5 (de)
WO1994004691A3 (en) Dimer and multimer forms of single chain polypeptides
BR9507594B1 (pt) anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteìna recombinante.
DE60230037D1 (de) Humanantikörper gegen blutgerinnungsfaktor viii
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
CY1109093T1 (el) Πρωτεϊνες των υποδοχεων θηλαστικων, σχετικα αντιδραστηρια και σχετικες μεθοδοι
BR0207151A (pt) Moléculas de aglutinação terapêuticas
WO2003048194A3 (de) Peptid oder protein enthaltend ein c'-d loop der cd28 rezeptorfamilie
DE50015629D1 (de) Verwendung cd28 spezifischer monoklonaler antikörpsetzung zur behandlung von virusinfektionen
DE60238556D1 (de) Humane antikörper gegen das humane glycoprotein vi und deren verwendung
EP1411962A4 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
van den Brink et al. Multiple VH genes are used to assemble human antibodies directed toward the A3-C1 domains of factor VIII
Welschof et al. The antigen binding domain of non-idiotypic human anti-F (ab′) 2 autoantibodies: study of their interaction with IgG hinge region epitopes

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1396539

Country of ref document: EP

REN Ceased due to non-payment of the annual fee